Adam Feuerstein ✡️ @adamfeuerstein · 02 Sep 2026
Ultragenyx $RARE announces Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome did not achieve primary endpoint
24 659Views
52Likes
2Reposts
7Replies
4Quotes
7Bookmarks
Is that a lot?
1.13×vs this author's median21 884 views is typical
75Percentile for this authorof 4 recent posts
1.11×vs 100K–1M median22 159 views is typical
18.80%Reachviews ÷ followers
0.26%Engagement rateof viewers reacted